Sinopharm Group Co Ltd (1099.HK) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sinopharm Group Co Ltd to acquire 66 pct equity interest in Sichuan Medicine Group


Monday, 18 Aug 2014 08:26am EDT 

Sinopharm Group Co Ltd:Entered into equity transfer agreement with CNPGC, the ultimate controlling shareholder of company, in respect of acquisition of 66 pct equity interest in Sichuan Medicine Group at consideration of 472 mln yuan.Says upon completion of the transaction under the Equity Transfer Agreement, Sichuan Medicine Group will become a subsidiary of the company.Says in addition, since Sichuan Medicine Group holds 51 pct equity interest in Sichuan Medicine, the company’s direct and indirect shareholding in Sichuan Medicine will be increased to 82.66 pct upon completion of aforesaid transaction. 

Related Company News

Company Quote

36.95
0.95 +2.64%
30 Jun 2016